JP5931845B2 - ２−メチレン−１９−ノル−２２−メチル−１α，２５−ジヒドロキシビタミンＤ３のジアステレオマー - Google Patents

２−メチレン−１９−ノル−２２−メチル−１α，２５−ジヒドロキシビタミンＤ３のジアステレオマー Download PDF

Info

Publication number
JP5931845B2
JP5931845B2 JP2013501403A JP2013501403A JP5931845B2 JP 5931845 B2 JP5931845 B2 JP 5931845B2 JP 2013501403 A JP2013501403 A JP 2013501403A JP 2013501403 A JP2013501403 A JP 2013501403A JP 5931845 B2 JP5931845 B2 JP 5931845B2
Authority
JP
Japan
Prior art keywords
compound
activity
mmol
ethyl acetate
sag
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2013501403A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013522370A (ja
JP2013522370A5 (enExample
Inventor
ヘクター エフ． デルカ
ヘクター エフ． デルカ
アグニエスツカ フローレス
アグニエスツカ フローレス
パウエル グジィヴァチュ
パウエル グジィヴァチュ
ローリ エイ． プラム
ローリ エイ． プラム
マーガレット クラーゲット−デイム
マーガレット クラーゲット−デイム
ジェイムス ビー． トーデン
ジェイムス ビー． トーデン
ヘイゼル エム． ホールデン
ヘイゼル エム． ホールデン
Original Assignee
ウイスコンシン アラムニ リサーチ ファンデーション
ウイスコンシン アラムニ リサーチ ファンデーション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ウイスコンシン アラムニ リサーチ ファンデーション, ウイスコンシン アラムニ リサーチ ファンデーション filed Critical ウイスコンシン アラムニ リサーチ ファンデーション
Publication of JP2013522370A publication Critical patent/JP2013522370A/ja
Publication of JP2013522370A5 publication Critical patent/JP2013522370A5/ja
Application granted granted Critical
Publication of JP5931845B2 publication Critical patent/JP5931845B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C401/00—Irradiation products of cholesterol or its derivatives; Vitamin D derivatives, 9,10-seco cyclopenta[a]phenanthrene or analogues obtained by chemical preparation without irradiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/14—All rings being cycloaliphatic
    • C07C2602/24—All rings being cycloaliphatic the ring system containing nine carbon atoms, e.g. perhydroindane
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Toxicology (AREA)
  • Transplantation (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
JP2013501403A 2010-03-23 2011-03-22 ２−メチレン−１９−ノル−２２−メチル−１α，２５−ジヒドロキシビタミンＤ３のジアステレオマー Expired - Fee Related JP5931845B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US31665310P 2010-03-23 2010-03-23
US61/316,653 2010-03-23
PCT/US2011/029452 WO2011119622A1 (en) 2010-03-23 2011-03-22 DIASTEREOMERS OF 2-METHYLENE-19-NOR-22-METHYL-1α,25- DIHYDROXYVITAMIN D3

Publications (3)

Publication Number Publication Date
JP2013522370A JP2013522370A (ja) 2013-06-13
JP2013522370A5 JP2013522370A5 (enExample) 2014-05-08
JP5931845B2 true JP5931845B2 (ja) 2016-06-08

Family

ID=44170381

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013501403A Expired - Fee Related JP5931845B2 (ja) 2010-03-23 2011-03-22 ２−メチレン−１９−ノル−２２−メチル−１α，２５−ジヒドロキシビタミンＤ３のジアステレオマー

Country Status (6)

Country Link
US (1) US20110237557A1 (enExample)
EP (1) EP2556054B1 (enExample)
JP (1) JP5931845B2 (enExample)
AU (1) AU2011232562B2 (enExample)
CA (1) CA2793727C (enExample)
WO (1) WO2011119622A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9212137B2 (en) * 2012-05-30 2015-12-15 Wisconsin Alumni Research Foundation Crystallization of (20R,22R)-2-methylene-19-nor-22-methyl-1α,25-dihydroxyvitamin D3 and related precursors
US9539231B2 (en) 2014-01-17 2017-01-10 The Regents Of The University Of Colorado, A Body Corporate Method for treating triple-negative breast cancer using AMPI-109

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5246925A (en) * 1989-03-09 1993-09-21 Wisconsin Alumni Research Foundation 19-nor-vitamin D compounds for use in treating hyperparathyroidism
CA1333616C (en) * 1989-03-09 1994-12-20 Hector F. Deluca 19-nor-vitamin d compounds
US5086191A (en) 1991-05-28 1992-02-04 Wisconsin Alumni Research Foundation Intermediates for the synthesis of 19-nor vitamin D compounds
JP3589413B2 (ja) * 1992-03-02 2004-11-17 幸子 山田 ２２−メチルビタミンｄ誘導体
JP2898882B2 (ja) * 1993-04-05 1999-06-02 ウイスコンシン アラムナイ リサーチ フオンデーシヨン ２−位に置換基を有する１９−ノル−ビタミンｄ３ 化合物
US5552392A (en) * 1993-11-03 1996-09-03 Wisconsin Alumni Research Foundation Method of treating hypoparathyroidism with (20S) vitamin D compounds
JP3567223B2 (ja) * 1995-07-31 2004-09-22 幸子 山田 カルシウム代謝改善剤
US6392071B1 (en) * 1997-03-17 2002-05-21 Wisconsin Alumni: Research Foundation 26,27-homologated-20-EPI-2-alkylidene-19-nor-vitamin D compounds
US5945410A (en) * 1997-03-17 1999-08-31 Wisconsin Alumni Research Foundation 2-alkyl-19-nor-vitamin D compounds
US5843928A (en) * 1997-03-17 1998-12-01 Wisconsin Alumni Research Foundation 2-alkylidene-19-nor-vitamin D compounds
US6316642B1 (en) * 1997-03-17 2001-11-13 Wisconsin Alumni Research Foundation 26,27-Homologated-20-EPI-2alkyl-19-nor-vitamin D compounds
US6306844B1 (en) * 1997-03-17 2001-10-23 Wisconsin Alumni Research Foundation Use of 2α-methyl-19-nor-20(S)-1α, 25-dihydroxyvitamin D3 to increase bone strength
US6114317A (en) * 1998-05-21 2000-09-05 Wisconsin Alumni Research Foundation Method of locking 1α-OH of vitamin D compounds in axial orientation
US6806262B2 (en) * 2000-05-31 2004-10-19 Wisconsin Alumni Research Foundation 2-ethyl and 2-ethylidene-19-nor-vitamin D compounds
EP1301189A2 (en) * 2000-07-14 2003-04-16 Wisconsin Alumni Research Foundation USE OF 2-METHYLENE-19-NOR-20(S)-1$g(a),25-DIHYDROXYVITAMIN D 3? TO INCREASE BONE STRENGTH
US6384087B1 (en) * 2000-09-01 2002-05-07 University Of Tennesseee Research Corporation, Inc. Materials and methods for the treatment or prevention of obesity
AU7544501A (en) * 2000-09-08 2002-03-22 Wisconsin Alumni Res Found 1alpha-hydroxy-2-methylene-19-nor-homopregnacalciferol and its therapeutic applications
US6835723B2 (en) * 2001-12-13 2004-12-28 Wisconsin Alumni Research Foundation 2-methylene-19-nor-20(S)-1α-hydroxy-bis-homo-pregnacalciferol in crystalline form
US6627622B2 (en) * 2002-02-18 2003-09-30 Wisconsin Alumni Research Foundation (20S)-1α-hydroxy-2-methylene-19-nor-bishomopregnacalciferol and its uses
US6566352B1 (en) * 2002-02-18 2003-05-20 Wisconsin Alumni Research Foudation 1 α-hydroxy-2-methylene-19-nor-pregnacalciferol and its uses
ATE346839T1 (de) * 2002-03-29 2006-12-15 Wisconsin Alumni Res Found Ein verfahren zur herstellung von 1-alpha-hydroxy-2-methylen-19-nor-homopregnacal iferol
US6846811B2 (en) * 2002-04-22 2005-01-25 Wisconsin Alumni Research Foundation (20S) 1α-hydroxy-2α-methyl and 2β-methyl-19-nor-vitamin D3 and their uses
US6894037B2 (en) * 2003-07-03 2005-05-17 Wisconsin Alumni Research Foundation 2-methylene-19-nor-20(S)-25-methyl-1α-hydroxycalciferol and its uses
NZ545862A (en) * 2003-08-20 2010-01-29 Wisconsin Alumni Res Found 2-Methylene-19-nor-vitamin D2 compounds
WO2005027913A1 (en) * 2003-09-19 2005-03-31 Pfizer Products Inc. Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and a growth hormone secretagogue
WO2005027931A1 (en) * 2003-09-19 2005-03-31 Pfizer Products Inc. Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and an ep2 or ep4 selective agonist
CA2539357A1 (en) * 2003-09-19 2005-03-31 Pfizer Products Inc. Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and parathyroid hormone
CA2539361A1 (en) * 2003-09-19 2005-03-31 Pfizer Products Inc. Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and an estrogen agonist/antagonist
US7214670B2 (en) * 2003-09-24 2007-05-08 Wisconsin Alumni Research Foundation Use of 2-methylene-19-nor-20(S)-1α,25-dihydroxyvitamin D3 to increase the life expectancy of human beings
US7704980B2 (en) * 2003-10-08 2010-04-27 Wisconsin Alumni Research Foundation Treatment of inflammatory bowel disease with 2-methylene-19-nor-vitamin D compounds
WO2005051323A2 (en) * 2003-11-25 2005-06-09 Wisconsin Alumni Research Foundation Vitamin d analogs for obesity prevention and treatment
WO2005051396A2 (en) * 2003-11-25 2005-06-09 Deltanoid Pharmaceuticals, Inc. Methods for reducing body fat using vitamin d compounds
WO2005079464A2 (en) * 2004-02-17 2005-09-01 Wisconsin Alumni Research Foundation Vitamin d receptor antagonists and their use in treating asthma
US7214671B2 (en) * 2004-02-19 2007-05-08 Wisconsin Alumni Research Foundation Use of 2-methylene-19-nor-20(S)-1α,25-dihydroxyvitamin D3 for the prophylaxis of bone diseases
US7713951B2 (en) * 2004-04-09 2010-05-11 Wisconsin Alumni Research Foundation 2-alkylidene-18,19-dinor-vitamin D compounds
AU2005309804B9 (en) * 2004-11-22 2011-12-08 Wisconsin Alumni Research Foundation 2alpha-methyl-19-nor-(20S)-1alpha-hydroxy-bishomopregnacalciferol and its uses
AU2005309806B2 (en) * 2004-11-22 2012-03-08 Wisconsin Alumni Research Foundation 2-methylene-19-nor-1alpha-hydroxy-17-ene-homopregnacalciferol and its uses
WO2006057884A2 (en) * 2004-11-22 2006-06-01 Wisconsin Alumni Research Foundation 2α-METHYL AND 2ß-METHYL ANALOGS OF 19,26,27-TRINOR-(20S)-1α-HYDROXYVITAMIN D3 AND THEIR USES
CA2588417C (en) * 2004-11-22 2012-09-18 Wisconsin Alumni Research Foundation 2-methylene-18,19-dinor-1.alpha.-hydroxy-homopregnacalciferol and its uses
DE602005021245D1 (de) * 2004-11-22 2010-06-24 Wisconsin Alumni Res Found 2-methylen-19,26,27-trinor-(20s)-1-alpha-hydroxyvitamin d3 and dessen verwendungen
EP1828115A4 (en) * 2004-11-22 2010-05-05 Wisconsin Alumni Res Found 2-METHYLENE-19-NOR (20S) -1ALPHA-HYDROXYTRISHOMOPREGNACALCIFEROL
CA2597624C (en) * 2005-02-11 2012-08-14 Wisconsin Alumni Research Foundation 2-methylene-19-nor-(20s-24s)-1.alpha.,25-dihydroxyvitamin-d2
US7511030B2 (en) * 2005-02-11 2009-03-31 Wisconsin Alumni Research Foundation 2-methylene-19-nor-(20S-24epi)-1α,25-dihydroxyvitamin D2
WO2006105221A1 (en) * 2005-03-29 2006-10-05 Wisconsin Alumni Research Foundation 2-METHYLENE-19-NOR-(23S)-25-DEHYDRO-1α-HYDROXYVITAMIN D3-26,23-LACTONE AND 2-METHYLENE-19-NOR-(23R)-25-DEHYDRO-1α-HYDROXYVITAMIN D3-26,23-LACTONE
AU2006242184A1 (en) * 2005-05-03 2006-11-09 Wisconsin Alumni Research Foundation 19,26,27-trinor-1alpha,25-dihydroxyvitamin D3 compounds
ATE523487T1 (de) * 2006-04-06 2011-09-15 Wisconsin Alumni Res Found 2-methylen-1-alpha-dihydroxy-19,21-dinor-vitami - d3-analoga und ihre anwendung
NZ570814A (en) * 2006-04-06 2011-11-25 Wisconsin Alumni Res Found 2-methylene-1alpha-hydroxy-19,21-dinorvitamin D3 analogs and uses thereof
EP2021321B1 (en) * 2006-04-06 2012-06-20 Wisconsin Alumni Research Foundation 2-methylene-1alpha,25-dihydroxy-18,19,21-trinorvitamin d3 and uses thereof
AU2007300214A1 (en) * 2006-09-28 2008-04-03 Wisconsin Alumni Research Foundation 2-methylene-(20R,25S)-19,27-dinor-(22E)-vitamin D analogs
US8377913B2 (en) * 2007-11-20 2013-02-19 Abbvie Inc. Vitamin D receptor activators and methods of making
US8609643B2 (en) * 2007-12-28 2013-12-17 Wisconsin Alumni Research Foundation 2-methylene-(20S,25R)-19,26-dinor-vitamin D analogs
CA2710954C (en) * 2007-12-28 2015-07-21 Wisconsin Alumni Research Foundation (20s)-23,23-difluoro-2-methylene-19-nor-bishomopregnacalciferol-vitamin d analogs
EP2237837B1 (en) * 2007-12-28 2012-08-22 Wisconsin Alumni Research Foundation (20r)-23,23-difluoro-2-methylene-19-nor-bishomopregnacalciferol-vitamin d analogs
CA2715811A1 (en) * 2008-03-06 2009-09-11 Wisconsin Alumni Research Foundation Methods of increasing epidermal skin thickness by topical administration of a 19-nor containing vitamin d compound
MX2010009814A (es) * 2008-03-10 2010-10-15 Wisconsin Alumni Res Found Compuestos con vitamina d y metodos para reducir la hipertension ocular.
US7888339B2 (en) * 2008-07-10 2011-02-15 Wisconsin Alumni Research Foundation 2-methylene-20(21)-dehydro-19-nor-vitamin D analogs
US8193170B2 (en) * 2008-07-10 2012-06-05 Wisconsin Alumni Research Foundation 2-methylene-19,26-dinor-(20R,22E,25R)-vitamin D analogs
US8399439B2 (en) * 2008-07-10 2013-03-19 Wisconsin Alumni Research Foundation 2-methylene-19,26-dinor-(20S,22E,25R)-vitamin D analogs
US7893043B2 (en) * 2008-07-10 2011-02-22 Wisconsin Alumni Research Foundation 2-methylene-(17Z)-17(20)-dehydro-19,21-dinor-vitamin D analogs
CA2764577C (en) * 2009-08-03 2017-12-19 Wisconsin Alumni Research Foundation Method of preventing renal disease and treating symptoms thereof
EP2525799B1 (en) * 2009-10-02 2014-09-03 Wisconsin Alumni Research Foundation (20s,22e)-2-methylene-19-nor-22-ene-1alpha,25-dihydroxyvitamin d3 analogs

Also Published As

Publication number Publication date
US20110237557A1 (en) 2011-09-29
JP2013522370A (ja) 2013-06-13
CA2793727A1 (en) 2011-09-29
EP2556054B1 (en) 2017-09-27
CA2793727C (en) 2017-01-03
EP2556054A1 (en) 2013-02-13
AU2011232562A1 (en) 2012-10-11
AU2011232562B2 (en) 2014-10-02
WO2011119622A1 (en) 2011-09-29

Similar Documents

Publication Publication Date Title
JP5113766B2 (ja) ビタミンｄ類似体：ｒａｋ、その方法および使用
JP2009525980A (ja) ビタミンｄ類似体：ｎｅｌ、その方法および使用
JP6383365B2 (ja) （２２Ｅ）−２−メチレン−２２−デヒドロ−１α，２４，２５−トリヒドロキシ−１９−ノル−ビタミンＤ３類似体
JP2008520689A (ja) １９，２６，２７−トリノル−（２０Ｓ）−１α−ヒドロキシビタミンＤ３の２α−メチルおよび２β−メチル類似体およびそれらの使用
JP2011507966A (ja) ２−メチレン−２０−メチル−１９，２４，２５，２６，２７−ペンタノル−ビタミンｄ類縁体
JP2010504995A (ja) ２−メチレン−（２０ｒ，２５ｓ）−１９，２７−ジノル−（２２ｅ）−ビタミンｄ類縁体
JP5770261B2 (ja) （２０Ｓ）−２−メチレン−１９−ノル−２２−ジメチル−１α，２５−ジヒドロキシビタミンＤ３および（２０Ｒ）−２−メチレン−１９−ノル−２２−ジメチル−１α，２５−ヒドロキシビタミンＤ３
JP2008520705A (ja) ２−メチレン−１９−ノル−１α−ヒドロキシ−１７−エン−ホモプレグナカルシフェロールおよびその使用
JP2008520691A (ja) ２−メチレン−１９，２６，２７−トリノル−（２０Ｓ）−１α−ヒドロキシビタミンＤ３およびその使用
JP2008530110A (ja) ２−メチレン−１９−ノル−（２０Ｓ−２４Ｓ）−１α，２５−ジヒドロキシビタミン−Ｄ２
JP2008520709A (ja) ２−メチレン−１９−ノル−（２０Ｓ）−１α−ヒドロキシ−トリスホモプレグナカルシフェロール
JP5629682B2 (ja) ２−メチレン−（１７ｚ）−１７（２０）−デヒドロ−１９，２１−ジノル−ビタミンｄ類似物質
JP2010504994A (ja) ２−メチレン−（２０ｓ，２５ｓ）−１９，２７−ジノル−（２２ｅ）−ビタミンｄ類縁体
JP5036565B2 (ja) ２−メチレン−１９−ノル−（２０Ｓ−２４エピ）−１α，２５−ジヒドロキシビタミン−Ｄ２
US7235680B2 (en) 2-methylene-19-nor-(23S)-25-dehydro-1α-hydroxyvitamin D3-26,23-lactone and 2-methylene-19-nor-(23R)-25-dehydro-1α-hydroxyvitamin D3-26,23-lactone
JP5931845B2 (ja) ２−メチレン−１９−ノル−２２−メチル−１α，２５−ジヒドロキシビタミンＤ３のジアステレオマー
JP2008520708A (ja) ２−メチレン−１９−ノル−（２０Ｒ）−１α−ヒドロキシ−ビスホモプレグナカルシフェロール
US8664206B2 (en) Diastereomers of 2-methylene-19-nor-22-methyl-1α,25-dihydroxyvitamin D3
JP2011527700A (ja) ２−メチレン−２０（２１）−デヒドロ−１９−ノル−ビタミンｄ類似物質
JP2008520716A (ja) ２−メチレン−１８，１９−ジノル−１α−ヒドロキシ−ホモプレグナカルシフェロール及びその使用
JP2011527698A (ja) ２−メチレン−（２０ｅ）−２０（２２）−デヒドロ−１９−ノル−ビタミンｄ類似物質
US20110294764A1 (en) 2-METHYLENE-19,26-NOR-(20S)-1alpha-HYDROXYVITAMIN D3
JP5036548B2 (ja) ２−メチレン−１９，２１−ジノル−１α−ヒドロキシ−ビスホモプレグナカルシフェロール
JP2009533418A (ja) １，１−ジメチルプロピル側鎖を持つ１α−ヒドロキシ−２−（３’−ヒドロキシプロピリデン）−１９−ノル−ビタミンＤ化合物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140318

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20140318

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20141224

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150323

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150423

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150522

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20150526

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20151021

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160219

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160222

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160224

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20160316

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20160404

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20160427

R150 Certificate of patent or registration of utility model

Ref document number: 5931845

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees